» Download Public Reports
About 200 reports
- Country report
- March 2013
- 44 pages
... Upstream sectors pharmaceutical industry activities altogether concur to the country health and wealth research & development production market access summary competitive ...
December 2012
... The next highest growth in sales. T_he intes- tinal anti-inflammatory drug class, which consists of the 5 aminosalicylates and several corticosteroids such as budesonide and hydrocortisone, dominates ...
December 2012
... Of the new shares will be locked up for a period of 4 months. Key new shareholders are investor ab and healthcap. About newron pharmaceuticals newron (six: nwrn) is a biopharmaceutical company focused ...
January 2013
... Effectiveness ratio. Methods. We designed a postinfarction scenario wherein heart rate variability analysis on 24-h holter monitoring was used as a screening test for 2-year amiodarone therapy in a cohort of survivors ...
October 2012
... The graph shows a geographical breakdown of our pharmaceutical revenue. As you can see, that we are growing our presence compared to last year in turkey. We are now in russia and you know, in the other ...
February 2013
... Company, entered into an agreement granting orphan europe the exclusive rights for the commercialization and distribution of graspa for the treatment of acute lymphoblastic leukemia (all) and acute ...
January 2013
... antiplatelets) 01/01/2006 inclusion criteria Persons aged 65 yrs or more on 01/01/2007 (n = 592,160) Discharged with ami* (icd9 : 410.) As principal diagnosis during the recruitment period exclusion criteria ...
November 2012
... Ingredient as branded products. At the beginning of the campaign 72% of consumers said they would use a generic medicine and this rose to 77% after the campaign. generic medicines rose 5% as a proportion ...
» Purchase Premium Reports
(From $ 250 - $ 6 995)
About 900 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
